Logo of Telix Pharmaceuticals (ASX:TLX)Latest Telix Pharmaceuticals (ASX:TLX) News

Page 1
Page 1 of 5

Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Prominence Energy doubled as hydrogen speculation drove the week’s biggest move, while takeover news lifted RAS Technology and Cleanaway.
Zip Co and several resource developers fell as investors weighed costs, capital needs and delivery risks.
Logan Eniac
24 Oct 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

Telix Q3 revenue rises 19% as ITM merger and Pixclara reshape growth story

Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.
Ada Torres
21 Oct 2026

Telix gains FDA Fast Track status for pre-biopsy prostate imaging program

Telix has secured FDA Fast Track designation for BiPASS, its Phase 3 program testing 68Ga-PSMA-PET alongside MRI before prostate biopsy. The milestone may support closer FDA engagement and faster review of a planned NDA, but the indication remains investigational and no BiPASS results were disclosed.
Victor Sage
30 Sept 2026

Market Wrap - Week 39 (21 Sept -> 25 Sept) 2026

Small-cap resources led the week’s biggest moves, but sharp falls in Bounty Oil and Nyrada showed how quickly investors can sell when funding and deal terms remain uncertain.
Gold, copper, rare earths and takeover activity supplied the strongest gains, while several companies still need more cash before they can deliver their plans.
Logan Eniac
26 Sept 2026

Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.
Logan Eniac
26 Sept 2026

Telix bets US$1.65 billion on ITM and a faster route into radiopharmaceutical therapies

Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
Ada Torres
21 Sept 2026

Market Wrap - Week 38 (14 Sept -> 18 Sept) 2026

Small-cap resources led the week, while takeover offers and defence contracts added support across the market.
Investors still had to weigh approvals, cash needs and project delivery against strong headline results.
Logan Eniac
19 Sept 2026

Telix Wins First FDA Approval for Glioma FET-PET Imaging Drug

Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.
Victor Sage
14 Sept 2026

Market Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Small-cap shares produced another uneven week, led by a major fall in Corporate Travel Management and strong gains in energy, gas and takeover stocks.
Investors rewarded rising profits and new deals, but sold several companies despite promising project news.
Logan Eniac
5 Sept 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

Telix Completes Phase 3 BiPASS Enrollment, Secures FDA Alignment for Prostate Cancer Imaging

Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.
Ada Torres
2 Sept 2026